Advertisement

Platelet-Derived Growth Factor Receptor (PDGF-R) as the Target for Herbal-Based Anticancer Agents

  • Manjula Devi Ramamoorthy
  • Kannan Narayanan Dhiraviam
Chapter

Abstract

In the preceding few years, there has been an exponential development in the field of herbal medicine against cancers due to their natural origin and relatively less adverse reactions than chemotherapy. For quite some time, plant-based molecules have been a source of therapeutic agents, and they keep on playing a crucial part as new investigational drugs against different illnesses including malignancy. The herbal products interact with a wide assortment of proteins, for example, catalysts, transcription factors, inflammatory cytokines, and gene products, correlated with cancer cell survival, invasion, proliferation, migration, and angiogenesis. Most fatal illnesses are caused by alterations of nearly 500 unique genes. The vast group of protein tyrosine kinase functions as a component of signaling pathways and tends to be fundamental for the transforming activity of normal cells into cancerous cells. In which, platelet-derived growth factor receptor (PDGF-R) has a prominent part in the initiation of cell signaling pathways. Platelet-derived growth factor (PDGF) isoforms and their receptors play a vital role in the direction of development and survival of cancer cells. In diseased condition, upgraded motioning of this receptor is the trademark. In particular cases, the persistence of PDGF signaling is fundamental to the survival of malignant cells. Thus, hindrance of PDGF receptor signaling has turned out to be valuable for curing patients with certain rare tumors. The advancement of receptor tyrosine kinase inhibitors that can obstruct diseases caused by abnormalities in this signaling pathway is considered as a promising methodology for the drug development. These drug revelation endeavors have created inhibitors and low molecular weight therapeutics coordinated against the ATP-restricting locales of protein kinases. The aim of this chapter is to discuss the production of plant secondary metabolites that might block tumor metastasis by targeting PDGF-R phosphorylation.

Keywords

Metastasis Angiogenesis Plant secondary metabolites Platelet-derived growth factor Receptor Tyrosine kinases 

References

  1. Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22:1276–1312CrossRefPubMedPubMedCentralGoogle Scholar
  2. Bae YS, Sung JY, Kim OS, Kim YJ, Hur KC, Kazlauskas A, Rhee SG (2000) Plateletderived growth factor-induced H2O2 production requires the activation of phosphatidylinositol 3-kinase. J Biol Chem 275:10527–10531CrossRefPubMedGoogle Scholar
  3. Ball SG, Shuttleworth CA, Kielty CM (2007) Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 177:489–500CrossRefPubMedPubMedCentralGoogle Scholar
  4. Banziger-Tobler NE, Halin C, Kajiya K, Detmar M (2008) Growth hormone promotes lymphangiogenesis. Am J Pathol 173:586–597CrossRefPubMedPubMedCentralGoogle Scholar
  5. Baxter RM, Secrist JP, Vaillancourt RR, Kazlauskas A (1998) Full activation of the platelet- derived growth factor beta-receptor kinase involves multiple events. J Biol Chem 273:17050–17055CrossRefPubMedGoogle Scholar
  6. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592–603CrossRefPubMedPubMedCentralGoogle Scholar
  7. Bonner JC (2004) Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15:255–273CrossRefPubMedGoogle Scholar
  8. Bonthron DT, Morton CC, Orkin SH, Collins T (1988) Platelet- derived growth factor A chain: gene structure, chromosomal location, and basis for alternative mRNA splicing. Proc Natl Acad Sci USA 85:1492–1496CrossRefPubMedGoogle Scholar
  9. Cao R, Bjorndahl MA, Religa P, Clasper S, Garvin S, Galter D (2004) PDGF-BB induces intra-tumor lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6:333–345CrossRefPubMedGoogle Scholar
  10. Cao L, Liu H, Lam DS, Yam GH, Pang CP (2010) In vitro screening for angiostatic potential of herbal chemicals. Invest Ophthalmol Vis Sci 51:6658–6664CrossRefPubMedGoogle Scholar
  11. Cao Y, Arbiser J, Amato RJ, Amore PA, Ingber DE, Kerbel R (2011) Forty-year journey of angiogenesis translational research. Sci Transl Med 3:114Google Scholar
  12. Center MM, Jemal A, Tieulent LJ, Ward E, Ferlay J, Brawley O, Bray F (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61:1079–1092CrossRefPubMedGoogle Scholar
  13. Chan CM, Chang HH, Wang VC, Huang CL, Hung CF (2013) Inhibitory effects of resveratrol on PDGF-BB-induced retinal pigment epithelial cell migration via PDGFRb, PI3K/Akt and MAPK pathways. PLoS One 8:e56819CrossRefPubMedPubMedCentralGoogle Scholar
  14. Chiara F, Bishayee S, Heldin CH, Demoulin JB (2004) Autoinhibition of the platelet derived growth factor beta- receptor tyrosine kinase by its C-terminal tail. J Biol Chem 279:19732–19738CrossRefPubMedGoogle Scholar
  15. Chou LB, Mann RA, Coughlin MJ, McPeake WT, Mizel MS (2007) Stress fracture as a complication of autogenous bone graft harvest from the distal tibia. Foot Ankle Int 28:199–201CrossRefPubMedGoogle Scholar
  16. Daniel EM, Kropnick AS, Heur YH, Blinzler JA, Nims RW, Stoner GD (1990) Extraction, stability, and quantitation of ellagic acid in various fruit and nuts. J Food Compos Anal 2:338–349CrossRefGoogle Scholar
  17. Fei XF, Wang BX, Li TJ, Tashiro S, Minami M, Xing DJ, Ikejima T (2003) Evodiamine, a constituent of evodiae fructus, induces anti-proliferating effects in tumor cells. Cancer Sci 94:92–98CrossRefPubMedGoogle Scholar
  18. Fidler IJ (2002) The organ microenvironment and cancer metastasis. Differentiation 70:498–505CrossRefPubMedGoogle Scholar
  19. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent. J Natl Cancer Inst 82:4–6CrossRefGoogle Scholar
  20. Fredriksson L, Li H, Fieber C, Li X, Eriksson U (2004a) Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J 23:3793–3802CrossRefPubMedPubMedCentralGoogle Scholar
  21. Fredriksson L, Li H, Eriksson U (2004b) The PDGF family: four gene products from five dimeric isoforms. Cytokine Growth Factor Rev 15:197–204CrossRefPubMedGoogle Scholar
  22. Fujiki H, Suganuma M, Okabe S (1998) Cancer inhibition by green tea. Mutat Res 402:307–310CrossRefPubMedGoogle Scholar
  23. Gao BB, Hansen H, Chen HC, Feener EP (2006) Angiotensin II stimulates phosphorylation of an ectodomain-truncated platelet-derived growth factor receptorbeta and its binding to class IA PI3K in vascular smooth muscle cells. Biochem J 397:337–344CrossRefPubMedPubMedCentralGoogle Scholar
  24. Gill RS, Hsiung MS, Sum CS, Lavine N, Clark SD, Van Tol HH (2010) The dopamine D4 receptor activates intracellular platelet-derived growth factor receptor beta to stimulate ERK1/2. Cell Signal 22:285–290CrossRefPubMedGoogle Scholar
  25. Gotink KJ, Verheul HM (2010) Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action. Angiogenesis 13:1–14CrossRefPubMedGoogle Scholar
  26. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312CrossRefPubMedGoogle Scholar
  27. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70CrossRefGoogle Scholar
  28. Heeneman S, Haendeler J, Saito Y, Ishida M, Berk BC (2000) Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor. Key role for the p66 adaptor protein Shc. J Biol Chem 275:15926–15932CrossRefPubMedGoogle Scholar
  29. Heldin CH (2013) Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal 11:97.  https://doi.org/10.1186/1478-811X-11-97 CrossRefPubMedPubMedCentralGoogle Scholar
  30. Heldin CH, Ostman A, Ronnstrand L (1998) Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1378:F79–113PubMedGoogle Scholar
  31. Heldin CH, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure – an obstacle in cancer therapy. Nat Rev Cancer 4:806–813CrossRefPubMedGoogle Scholar
  32. Helfrich I, Edler L, Sucker A, Thomas M, Christian S, Schadendorf D (2009) Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 15:1384–1392CrossRefPubMedGoogle Scholar
  33. Heo SK, Yun HJ, Yi HS, Noh EK, Park SD (2009) Evodiamine and rutaecarpine inhibit migration by light via suppression of NAPDH oxidase activation. J Cell Biochem 107:123–133CrossRefPubMedGoogle Scholar
  34. Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, Lawrance J, Carrington B, Roberts C, Issa B (2005) Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEgylated di-Fab’, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 11:973–981CrossRefGoogle Scholar
  35. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon- Cardo C, Beug H, Grunert S (2006) Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 116:1561–1570CrossRefPubMedPubMedCentralGoogle Scholar
  36. Jensen LD, Cao R, Cao Y (2009) In vivo angiogenesis and lymphangiogenesis models. Curr Mol Med 9:982–991CrossRefPubMedGoogle Scholar
  37. Jiang J, Hu C (2009) Evodiamine: A novel anti-cancer alkaloid from Evodia rutaecarpa. Molecules 14:1852–1859CrossRefPubMedGoogle Scholar
  38. Jurek A, Amagasaki K, Gembarska A, Heldin CH, Lennartsson J (2009) Negative and positive regulation of MAPK phosphatase 3 controls platelet-derived growth factor-induced Erk activation. J Biol Chem 284:4626–4634CrossRefPubMedGoogle Scholar
  39. Khoshkam V, Chan HL, Lin GH, Mailoa J, Giannobile WV, Wang HL, Oh TJ (2015) Outcomes of regenerative treatment with rhPDGF-BB and rhFGF-2 for periodontal intra-bony defects: a systematic review and meta-analysis. J Clin Periodontol 42:272CrossRefPubMedGoogle Scholar
  40. Kim DS, Kwon HM, Choi JS, Kang SW, Ji GE (2007) Resveratrol blunts tumor necrosis factor alpha-induced monocyte adhesion and transmigration. Nutr Res Pract 1:285–290CrossRefPubMedPubMedCentralGoogle Scholar
  41. Kunnumakkara AB, Anand P, Aggarwal BB (2008) Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269:199–225CrossRefPubMedGoogle Scholar
  42. Labrecque L, Lamy S, Chapus A, Mihoubi S, Duroche Y, Cass B, Bojanowski MW, Gingras D, Beliveau R (2005) Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis 26:821–826CrossRefPubMedGoogle Scholar
  43. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117–1134CrossRefPubMedPubMedCentralGoogle Scholar
  44. Liu Z, Butow RA (2006) Mitochondrial retrograde signaling. Annu Rev Genet 40:159–185CrossRefPubMedGoogle Scholar
  45. Lu K, Bhat M, Basu S (2016) Plants and their active compounds: natural molecules to target angiogenesis. Angiogenesis 19:287–295CrossRefPubMedPubMedCentralGoogle Scholar
  46. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteasome pathway in prostate cancer cells. Cancer Res 62:2478–2482PubMedGoogle Scholar
  47. Martel MD, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13:607–615CrossRefPubMedGoogle Scholar
  48. Masamune A, Kikuta K, Satoh M, Suzuki N, Shimosegawa T (2005) Green tea polyphenol epigallocatechin-3-gallate blocks PDGF-induced proliferation and migration of rat pancreatic stellate cells. World J Gastroenterol 11:3368–3374CrossRefPubMedPubMedCentralGoogle Scholar
  49. Mihaly Z, Sztupinszki Z, Surowiak P, Gyorffy B (2012) A comprehensive overview of targeted therapy in metastatic renal cell carcinoma. Curr Cancer Drug Targets 12:857–872CrossRefPubMedPubMedCentralGoogle Scholar
  50. Mukherjee AK, Basu S, Sarkar N, Ghosh AC (2001) Advances in cancer therapy with plant based natural products. Curr Med Chem 8:1467–1486CrossRefPubMedGoogle Scholar
  51. Omura T, Heldin CH, Ostman A (1997) Immunoglobulin-like domain 4-mediated receptor- receptor interactions contribute to platelet-derived growth factor-induced receptor dimerization. J Biol Chem 272:12676–12682CrossRefPubMedGoogle Scholar
  52. Ostman A (2004) PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15:275–286CrossRefPubMedGoogle Scholar
  53. Papetti M, Herman IM (2002) Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282:C947–C970CrossRefPubMedGoogle Scholar
  54. Pennock S, Kazlauskas A (2012) Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses. Mol Cell Biol 32:1955–1966CrossRefPubMedPubMedCentralGoogle Scholar
  55. Perros F, Montani D, Dorfmuller P, Gasselin D, Tcherakian C, Pavec J, Mazmanian M, Fadel E, Mussot S, Mercier O, Herve P, Emilie D, Eddahibi S, Simonneau G, Souza R, Humbert M (2008) Platelet derived growth factor expression and function in idiopathic pulmonary aterial hypertension. Am J Resp Crit Care Med 178:81–88CrossRefPubMedGoogle Scholar
  56. Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A (2003) PDGF receptors as cancer drug targets. Cancer Cell 3:439–443CrossRefPubMedGoogle Scholar
  57. Ribatti D, Djonov V (2012) Intussusceptive microvascular growth in tumors. Cancer Lett 316:126–131CrossRefPubMedGoogle Scholar
  58. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671–674CrossRefPubMedGoogle Scholar
  59. Sakarkar DM, Deshmukh VN (2011) Ethnopharmacological review of traditional medicinal plant for anticancer activity. Int J Pharm Tech 3:298–308Google Scholar
  60. Shen J, Vil MD, Zhang H, Tonra JR, Rong LL, Damoci C, Prewett M, Deevi DS, Kearney J, Surguladze D (2007) An antibody directed against PDGF receptor β enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody. Biochem Biophys Res Commun 357:1142–1147CrossRefPubMedGoogle Scholar
  61. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics 2016. CA Cancer J Clin 66:7–30CrossRefGoogle Scholar
  62. Socinski MA (2011) Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer. Cancer Treat Rev 37:611–617CrossRefPubMedGoogle Scholar
  63. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, Gao Y, Pietras K, Mann K, Yepes M, Strickland DK, Betsholtz C, Eriksson U, Lawrence DA (2008) Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 14:731–737CrossRefPubMedPubMedCentralGoogle Scholar
  64. Torre LA, Bray F, Siegel RL, Ferlay J, Tieulent JL, Jemal A (2015) Global cancer statistics 2012. CA Cancer J Clin 65:87–108CrossRefGoogle Scholar
  65. Venkatesan B, Valente AJ, Reddy VS, Siwik DA, Chandrasekar B (2009) Resveratrol blocks interleukin-18-EMMPRIN cross-regulation and smooth muscle cell migration. Am J Physiol Heart Circ Physiol 297:H874–H886CrossRefPubMedPubMedCentralGoogle Scholar
  66. Wang T, Wang Y, Kontani Y, Kobayashi Y, Sato Y, Mori N, Yamashita H (2008) Evodiamine improves diet-induced obesity in a uncoupling protein-1-independent manner: involvement of antiadipogenic mechanism and extracellularly regulated kinase/mitogen-activated protein kinase signaling. Endocrinology 149:358–366CrossRefPubMedGoogle Scholar
  67. Wang CZ, Calway T, Yuan CS (2012) Herbal medicine as adjuvants for cancer therapeutics. Am J Chin Med 40:657–669CrossRefPubMedPubMedCentralGoogle Scholar
  68. Wang P, Song L, Ge H, Jin P, Jiang Y, Hu W, Geng N (2014) Crenolanib, a PDGFR inhibitor suppresses lung cancer cell proliferation and inhibits tumor growth in vivo. Oncol Targets Ther 7:1761–1768CrossRefGoogle Scholar
  69. Wardega P, Heldin CH, Lennartsson J (2010) Mutation of tyrosine residue 857 in the PDGF beta-receptor affects cell proliferation but not migration. Cell Signal 22:1363–1368CrossRefPubMedGoogle Scholar
  70. Weber AA, Neuhaus T, Skach RA, Hescheler J, Ahn HY, Schror K, Ko Y, Sachinidis A (2004) Mechanism of the inhibitory effects of epigallocatechin-3 gallate on platelet – derived growth factor-BB induced cell signaling and mitogenesis. FASEB J 18:128–130CrossRefPubMedGoogle Scholar
  71. Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68:3077–3080CrossRefPubMedGoogle Scholar
  72. Weiss L (2000) Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev 19:193–400CrossRefGoogle Scholar
  73. Wilhelm SM, Carter C, Tang L (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109CrossRefPubMedGoogle Scholar
  74. Yang Y, Yuzawa S, Schlessinger J (2008a) Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization. Proc Natl Acad Sci USA 105:7681–7686CrossRefPubMedGoogle Scholar
  75. Yang J, Wu LJ, Tashiro S, Onodera S, Ikejima T (2008b) Nitric oxide activated by p38 and NF- kappaB facilitates apoptosis and cell cycle arrest under oxidative stress in evodiamine-treated human melanoma A375-S2 cells. Free Radic Res 42:1–11CrossRefPubMedGoogle Scholar
  76. Yang G, Li X, Li X, Wang L, Li J, Song X (2012) Traditional Chinese medicine in cancer care: a review of case series published in the Chinese literature. Evid Based Complement Alternat Med 2012:751046.  https://doi.org/10.1155/2012/751046 CrossRefPubMedPubMedCentralGoogle Scholar
  77. Yang J, Cai X, Lu W, Hu C, Xu X, Yu Q, Cao P (2013) Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof in hepatocellular carcinoma cells. Cancer Lett 328:243–251CrossRefPubMedGoogle Scholar
  78. Yehya AHS, Asif M, Tan YJ, Sasidharan S, Majid AMSA, Einoon C (2017) Broad spectrum targeting of tumor vasculature by medicinal plants: An updated review. J Herbal Med.  https://doi.org/10.1016/j.hermed.2017.03.003
  79. Zheng S, Chen A (2006) Curcumin suppresses the expression of extracellular matrix genes in activated hepatic stellate cells by inhibiting gene expression of connective tissue growth factor. Am J Physiol Gastrointest Liver Physiol 290:G883–G893CrossRefPubMedGoogle Scholar
  80. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541PubMedGoogle Scholar
  81. Zhou Y, Zheng S, Lin J, Zhang QJ, Chen A (2007) The interruption of the PDGF and EGF signaling pathways by curcumin stimulates gene expression of PPAR gamma in rat activated hepatic stellate cell in vitro. Lab Investig 5:488–498CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Manjula Devi Ramamoorthy
    • 1
  • Kannan Narayanan Dhiraviam
    • 1
  1. 1.Department of Plant Biotechnology, School of BiotechnologyMadurai Kamaraj UniversityMaduraiIndia

Personalised recommendations